Importance Early administration of antibiotics in the absence of proven sepsis, such as for treatment of early-onset sepsis (EOS), has been associated with adverse outcomes in very preterm infants. Reference values for procalcitonin (PCT) and presepsin (P-SEP) have been established in preterm infants. Objective To determine whether PCT- and P-SEP–guided antibiotic treatment for EOS was noninferior to universal antibiotic treatment with respect to survival without major morbidity. Design, Setting, and Participants This randomized multicenter noninferiority clinical trial was conducted in 17 Italian neonatal intensive care units between June 1, 2023, and January 31, 2025, among preterm infants born at 25 weeks and 0 days to 31 weeks and 6 days of gestation. Interventions Enrolled infants were randomly allocated to receive either PCT- and P-SEP–guided antibiotic treatment, administered if PCT and P-SEP levels exceeded prespecified thresholds, or universal antibiotic treatment for EOS. Main Outcomes and Measures The composite primary outcome was defined as survival without late-onset sepsis (LOS), bronchopulmonary dysplasia, grade 3 or 4 intraventricular hemorrhage (IVH), grade 2 or higher necrotizing enterocolitis (NEC), periventricular leukomalacia (PVL), or stage 3 or higher retinopathy of prematurity (ROP). The prespecified noninferiority margin was −5 percentage points. Both a primary intention-to-treat analysis and a secondary per-protocol analysis were performed, as recommended for noninferiority trials. Results The study enrolled and randomized 283 very preterm infants (mean [SD] gestational age, 30.2 [2.2] weeks; 161 girls [57%]); 143 received procalcitonin- and presepsin-guided treatment and 140 received universal antibiotic treatment. The primary outcome did not differ between the PCT- and P-SEP–guided treatment group and the universal antibiotic treatment groups (76 of 143 [53%] vs 77 of 140 [55%]; risk difference, −1.8 percentage points; 90% CI, −11.9 to 8.3 percentage points; P = .32). Noninferiority of PCT- and P-SEP–guided treatment compared with universal treatment was not demonstrated, because the lower bound of the 2-sided 90% CI crossed the prespecified noninferiority margin. The risk differences for LOS, IVH, NEC, PVL, ROP, and death were not significantly different between the groups. PCT and P-SEP values were not different between the groups. No patient developed EOS. Conclusions and Relevance In this randomized clinical trial conducted among neonates born between 25 weeks and 0 days and 31 weeks and 6 days of gestation, a PCT- and P-SEP–guided strategy for the treatment of EOS did not demonstrate noninferiority to universal antibiotic treatment with respect to survival without major morbidity. Within the limits of this study, these findings do not support the routine use of a biomarker-guided approach as an alternative to universal treatment for this high-risk population. Trial Registration Clinicaltrials.gov identifier: NCT05796115
Background : Nonadherence is a major cause of relapse in patients with schizophrenia, schizoaffective disorder, or bipolar disorder who have achieved remission. However, it is also a significant challenge during manic episodes. Risperidone in-situ microimplant (ISM) releases the drug early and in a sustained manner once a month, eliminating the need for daily administration, which can be difficult during a manic episode. In this study, we examined the short-term efficacy and tolerability of risperidone ISM in real-world nonadherent inpatients with schizoaffective disorder experiencing a manic episode with psychotic symptoms. Methods : This retrospective, observational, single-centre study included 50 consecutive adults admitted after discontinuation/marked non-adherence and with prior response to risperidone received ≥6 days of oral risperidone to confirm tolerability, then risperidone ISM (75 or 100 mg) and were followed for 6 weeks. Mania severity was assessed with the Young Mania Rating Scale (YMRS). Results : Fifty patients were included; most received concomitant mood stabilisers and benzodiazepines. Median YMRS decreased from 32 at admission to 26 at first injection (after the oral lead-in), 8 by day 8, and remained low at day 28 (5) and day 42 (6). Activation/behavioural items improved earlier, whereas psychotic thought content improved more gradually, predominantly between days 8 and 28. Side-effect burden at weeks 4 and 6 was minimal, and no discontinuations due to adverse events occurred. Conclusions : In this exploratory uncontrolled cohort, oral risperidone lead-in plus monthly risperidone ISM within multimodal inpatient care was associated with rapid and sustained improvement and favourable short-term tolerability. These findings should be interpreted as resulting from a combination of ISM treatment and a structured inpatient strategy, rather than as evidence of the effect of ISM alone. Prospective, controlled studies are warranted.
Obesity is a chronic relapsing disease associated with increased morbidity and mortality and reduced quality of life. The present GRADE-based guidelines have been commissioned by the Italian Society of Obesity (SIO) by the Italian National Health Institute to provide evidence-based recommendations on obesity diagnosis and treatment. The panel identified 13 clinical questions, organised into four domains: A. diagnostic criteria (4 questions); B. medical nutrition therapy (4 questions); C. pharmacological, surgical, and endoscopic treatments (4 questions); and D. miscellaneous (1 question). The expert panel recommends adopting at least one anthropometric index of abdominal visceral fat distribution beyond body mass index (BMI) for better clinical risk stratification. A structured lifestyle intervention (i.e., medical–nutritional treatment—MNT), preferably based on cognitive–behavioural therapeutic approach and including physical activity and a balanced diet, should be offered to all subjects living with obesity. Pharmacological or surgical treatment should be offered in addition to MNT when MNT is unable to reach clinical goals. In particular, pharmacological treatment should be considered as the preferred option for subjects with BMI > 27 kg/m2 with comorbidities, and for those with BMI 30–39.9 kg/m2, based on individual therapeutic goals and needs, adopting surgical treatment in selected cases or in case of OMM failure to reach clinical goals. For subjects with a BMI > 40 kg/m2, surgical treatment may be considered conversely as a preferable option. Reduction of at least 10
The association between insulin resistance (IR), type 2 diabetes mellitus (T2DM), and cancer is increasingly recognized and poses an escalating global health challenge, as the incidence of these conditions continues to rise. Studies indicate that individuals with T2DM have a 10–20
To assess the efficacy and safety of autologous cell therapy (ACT) in patients with ischemic diabetic foot ulcers (DFU). The present meta-analysis was designed to support the development of the Italian Guidelines for the Treatment of Diabetic Foot Syndrome (DFS). A Medline and Embase search were performed up to Feb 1st, 2024 collecting all RCTs including diabetic patients or reporting subgroup analyses on diabetic patients with ischemic foot ulcers comparing ACT with placebo/no therapy/standard of care (SoC), with a duration of at least 26 weeks. Prespecified endpoints were: major amputation (principal) and minor amputation, ulcer healing, time-to-healing, transcutaneous oxygen pressure (TcPO2), ankle-brachial index (ABI), pain, and all-cause mortality (secondary). Any ACT was allowed, irrespective of cell product type and route of administration (intra-arterial and intramuscular). Seven studies fulfilled all inclusion criteria, all using intramuscular transplantation as route of administration, but only 2 had a follow-up greater than 26 weeks. Participants treated with ACT had a significantly lower risk of major amputations in comparison with SoC/placebo (MH-OR 0.47 [0.24, 0.92], p = 0.03). ACT was also associated with a significantly higher rate of ulcer healing (MH-OR: 10.1 [3.5, 29.6], p < 0.001), greater increase of TcPO2 and ABI values (WMD: 17.57 [13.02, 22.12], p < 0.001), and reduction of pain (WMD: -1.83 [-2.32, -1.34], p = 0.003). ACT must be considered as a potential therapy for patients with ischemic diabetic foot ulcers. Further studies are needed to better clarify their role in the treatment and management of DFS.